V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]
Awaiting development
Reference number: GID-TA11881
Expected publication date: TBC
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. We will write to you in due course about how you can get involved.